Stuart Diamond: ApoB as a Key Marker of Cardiovascular Risk
Stuart Diamond, Scientific Director at Global Integral Beauty, Medical Doctor at Geneva College of Longevity Science, and Co-Founder at Equilux – Unlock Your Biology, shared a post on LinkedIn:
“For decades, cardiovascular risk has been assessed primarily through LDL-cholesterol.
But modern lipid science increasingly points to a more fundamental driver of atherosclerosis:
Apolipoprotein B (ApoB).
Every atherogenic lipoprotein particle – LDL, VLDL remnants, IDL, and Lp(a) – carries one ApoB molecule.
This means ApoB reflects the number of particles capable of penetrating the arterial wall and initiating plaque formation.
Two individuals can have identical LDL- C levels, yet one may have significantly more circulating atherogenic particles.
In simple terms:
- LDL-C measures cholesterol content.
- ApoB measures particle number.
Evidence continues to support this.
- Ference BA et al., European Heart Journal (2017) — genetic analyses showing cardiovascular risk proportional to cumulative exposure to ApoB lipoproteins.
- Sniderman AD et al., JAMA Cardiology (2019) — ApoB more accurately reflects atherogenic particle burden than LDL-C.
- Yusuf S et al., Lancet — INTERHEART study linking ApoB/ApoA1 ratio to myocardial infarction risk globally.
From a biological perspective the mechanism is straightforward.
Atherosclerosis begins when ApoB-containing lipoproteins cross the endothelium and become retained in the arterial intima, triggering inflammation and plaque formation.
The greater the number of circulating ApoB particles, the greater the probability of this process occurring.
Cardiovascular disease still remains the leading cause of mortality worldwide, often developing silently for decades.
Monitoring ApoB allows clinicians to detect and address risk earlier and more precisely.
Preventive targets commonly used in cardiology practices include:
- ApoB less than 80 mg/dL – moderate risk
- ApoB less than 60 mg/dL – high-risk prevention
- ApoB less than 50 mg/dL – aggressive prevention
Achieving these levels often requires lifestyle optimization and targeted therapy including statins, ezetimibe, PCSK9 inhibitors, or bempedoic acid.
What is becoming increasingly clear:
Atherosclerosis is fundamentally a disease of cumulative exposure to ApoB-containing particles.
Reducing that exposure earlier in life may be one of the most powerful ways to extend cardiovascular health and healthspan.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 15:56Anita Zaidi: Why Only 2% of Health Research and Development Goes to Women’s Conditions
-
Sep 21, 2026, 15:49Omid Khalafi: Gating Strategy and How Do We Decide Which Cells to Analyze
-
Sep 21, 2026, 15:44Levacetylleucine: A New Therapeutic Approach to Ataxia Telangiectasia
-
Sep 21, 2026, 15:40Andreas Tridimas: The Diagnostic Traps of Lipaemic Blood – Why a Normal Amylase Can Mislead You
-
Sep 21, 2026, 15:33Arsene Mekinian: Exploring Cardiac Involvement in Behçet’s Disease
-
Sep 21, 2026, 15:23Anis Mahjoubi: MRI Findings of Krukenberg Tumors
-
Sep 21, 2026, 15:08Fikreab Tesfaye Tefera: 10 Practical Take-Home Points for Diagnosing Iron Deficiency Anemia
-
Sep 21, 2026, 14:10Aswin K Mohan: Lessons from TRANSCON 2026 – Building Resilient Blood Supply Systems Before Crisis Hits
-
Sep 21, 2026, 14:00Vincent Lu: Beyond PT and aPTT – How Hemostasis Evolves Across a Lifetime